Abstract
Currently, approximately 95% of pancreatic cancers are pancreatic ductal adenocarcinoma (PDAC), which is the most aggressive form and the fourth leading cause of cancer death with extremely poor prognosis [1]. Poor prognosis is primarily attributed to the late diagnosis of the disease when patients are no longer candidates for surgical resection [2]. Cancer cells are dependent on the oncogenes that allow them to proliferate limitlessly. Thus, targeting the expression of known oncogenes in pancreatic cancer has been shown to lead to more effective treatment [3]. This chapter will discuss the complexity of metabolic features in pancreatic cancers. To be able to fully comprehend the heterogeneous nature of cancer metabolism, we need to take into account the close relationship between cancer metabolism and genetics. Gene expression varies tremendously, not only among different types of cancers, but also within the same type of cancer among different patients. Cancer metabolism heterogeneity is often prompted and perpetuated not only by genetic mutations in oncogenes and tumor suppressor genes but also by the innate diversity of the tumor microenvironment. Much effort has been focused on elucidating the genetic alterations that correlate with disease progression and treatment response [4]. However, the precise mechanism by which tumor metabolism contributes to cancer growth, survival, mobility, and aggressiveness represents a functional readout of tumor progression.
Keywords
Abbreviations
- ASP:
-
Aspartate
- EGFR:
-
Epidermal growth factor receptor
- GLS:
-
Glutaminase
- GLUD1:
-
Glutamate dehydrogenase 1
- GLUT:
-
Glucose transporter
- GOT1:
-
Glutamic-oxaloacetic transaminase 1
- HIF-1α:
-
Hypoxia-inducible factor 1-alpha
- HK2:
-
Hexokinase 2
- KRAS:
-
Kirsten rat sarcoma viral oncogene homolog
- LDH:
-
Lactate dehydrogenase
- MCT:
-
Monocarboxylate transporter
- OAA:
-
Oxaloacetate
- PDAC:
-
Pancreatic ductal adenocarcinoma
- PFK1:
-
Phosphofructokinase 1
- TCA:
-
Tricarboxylic acid cycle
References
Hariharan, D., Saied, A., & Kocher, H. M. (2008). Analysis of mortality rates for pancreatic cancer across the world. HPB: The Official Journal of the International Hepato Pancreato Biliary Association, 10(1), 58–62.
Hidalgo, M. (2010). Pancreatic cancer. The New England Journal of Medicine, 362(17), 1605–1617.
Weinstein, I. B., & Joe, A. (2008). Oncogene addiction. Cancer Research, 68(9), 3077–3080. discussion 3080.
Verhaak, R. G., et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17(1), 98–110.
Birnbaum, D. J., et al. (2011). Genome profiling of pancreatic adenocarcinoma. Genes, Chromosomes & Cancer, 50(6), 456–465.
Son, J., et al. (2013). Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature, 496(7443), 101–105.
Lyssiotis, C. A., et al. (2013). Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance. Cell Cycle, 12(13), 1987–1988.
di Magliano, M. P., & Logsdon, C. D. (2013). Roles for KRAS in pancreatic tumor development and progression. Gastroenterology, 144(6), 1220–1229.
Sousa, C. M., & Kimmelman, A. C. (2014). The complex landscape of pancreatic cancer metabolism. Carcinogenesis, 35(7), 1441–1450.
Ying, H., et al. (2012). Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell, 149(3), 656–670.
Chaika, N. V., et al. (2012). Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PLoS One, 7(3), e32996.
Maher, J. C., et al. (2005). Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas, 30(2), e34–e39.
Yun, J., et al. (2009). Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science, 325(5947), 1555–1559.
Chaika, N. V., et al. (2012). MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 109(34), 13787–13792.
Rajeshkumar, N. V., et al. (2015). Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function. Cancer Research, 75(16), 3355–3364.
Surget, S., Khoury, M. P., & Bourdon, J. C. (2013). Uncovering the role of p53 splice variants in human malignancy: A clinical perspective. Onco Targets and Therapy, 7, 57–68.
Bensaad, K., et al. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 126(1), 107–120.
Weinberg, S. E., & Chandel, N. S. (2015). Targeting mitochondria metabolism for cancer therapy. Nature Chemical Biology, 11(1), 9–15.
Alistar, A., et al. (2017). Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: A single-Centre, open-label, dose-escalation, phase 1 trial. The Lancet Oncology, 18(6), 770–778.
Stuart, S. D., et al. (2014). A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer & Metabolism, 2(1), 4.
Pardee, T. S., et al. (2014). A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clinical Cancer Research, 20(20), 5255–5264.
Sancho, P., et al. (2015). MYC/PGC-1alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metabolism, 22(4), 590–605.
Lonardo, E., et al. (2013). Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One, 8(10), e76518.
Evans, J. M., et al. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330(7503), 1304–1305.
Sadeghi, N., et al. (2012). Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clinical Cancer Research, 18(10), 2905–2912.
Viale, A., et al. (2014). Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature, 514(7524), 628–632.
Elgogary, A., et al. (2016). Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 113(36), E5328–E5336.
Rahib, L., et al. (2014). Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research, 74(11), 2913–2921.
Rossi, M. L., Rehman, A. A., & Gondi, C. S. (2014). Therapeutic options for the management of pancreatic cancer. World Journal of Gastroenterology, 20(32), 11142–11159.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Camelo, F., Le, A. (2018). The Intricate Metabolism of Pancreatic Cancers. In: Le, A. (eds) The Heterogeneity of Cancer Metabolism. Advances in Experimental Medicine and Biology, vol 1063. Springer, Cham. https://doi.org/10.1007/978-3-319-77736-8_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-77736-8_5
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-77735-1
Online ISBN: 978-3-319-77736-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)